Weight Loss Clinic in California: How Telehealth Weight Loss Works

15 min readWritten by Protocol Health Editorial TeamMedically reviewed by Richard Dentico, MDPublished Updated

A weight loss clinic in California can run entirely by telehealth, provided the prescriber holds a California license, you give documented consent to telehealth and the clinician meets the same standard of care as an office visit. Semaglutide and tirzepatide both produced large average weight loss in trials, both carry a boxed warning for thyroid C-cell tumors, and compounded versions are not FDA-approved.

Weight Loss Clinic in California: How Telehealth Weight Loss Works
Here’s what we’ll cover

Key takeaways

  • A telehealth weight loss clinic in California is a medical practice that evaluates you by video or secure questionnaire, orders labs if needed, and prescribes weight-loss medication only when a clinician licensed in California decides it is appropriate for you.
  • Protocol Health prescribes compounded semaglutide and compounded tirzepatide to patients in California when a licensed provider decides treatment is appropriate.
  • The difference between compounded and brand-name semaglutide is that the brand products are FDA-approved finished drugs and compounded versions are not.
  • Compounded semaglutide for a California patient is dispensed by a state-licensed pharmacy and shipped to your home.
  • Semaglutide and tirzepatide are both effective for weight loss, and in a head-to-head trial tirzepatide produced more.
  • Compounded semaglutide is not FDA-approved and is not the same as a brand-name product.

Short Answer

What Is a Telehealth Weight Loss Clinic in California?

A telehealth weight loss clinic in California is a medical practice that evaluates you by video or secure questionnaire, orders labs if needed, and prescribes weight-loss medication only when a clinician licensed in California decides it is appropriate for you. The visit happens on a screen, the care standard is the one an in-person doctor would meet, and a pharmacy ships the medication to your door. The Medical Board of California states that the standard of care is the same whether the patient is seen in person or through telehealth.

That is a different thing from the storefront weight loss clinic many Californians picture. A telehealth practice has no waiting room in your city, and the quality question moves from the lobby to the licensure, the screening and the pharmacy behind the prescription.

Protocol Health treats patients in California this way. We are licensed in New York, New Jersey, Connecticut, Florida and California, and our only in-person clinic is at 700 White Plains Rd #30 in Scarsdale, New York. There is no Protocol Health office anywhere in California, so for a California patient every visit is remote, apart from a blood draw at a lab near you.

Patients search for this care as a weight loss clinic, a medical weight loss program or an online weight loss doctor in California. All of these describe the same arrangement: a licensed clinician, a real evaluation and a prescription.

Disclosure: Protocol Health sells compounded semaglutide and compounded tirzepatide, so we have a commercial interest in this topic. This page rests on California's own statutes and board guidance, on FDA statements and on the published trials, and it weighs risks as heavily as benefits.

So a telehealth weight loss clinic in California is a licensed, remote version of ordinary medical care, and the license, the screening and the pharmacy are what to check.

In-Person Exam

Do You Need an In-Person Exam for Weight Loss Medication in California?

You do not need an in-person exam to get weight loss medication in California, but you do need an appropriate prior examination and a medical indication. Business and Professions Code 2242 makes it unprofessional conduct to prescribe dangerous drugs without both, and then adds that the prior examination "does not require a synchronous interaction between the patient and the licensee and can be achieved through the use of telehealth, including, but not limited to, a self-screening tool or a questionnaire, provided that the licensee complies with the appropriate standard of care."

The proviso at the end is the part that protects you. California allows a questionnaire, but it does not lower the bar. A clinician still has to review your history, weight, other conditions and medications, decide that treatment is indicated, and be able to defend that decision as meeting the standard of care.

In practice a sound California telehealth visit covers your weight history, blood pressure, personal and family history of thyroid cancer, pancreatitis, gallbladder disease, diabetes, pregnancy plans and the other medicines you take. Many clinicians also order bloodwork before the first prescription. A clinic that skips all of that and asks only for a credit card is not following the statute's own logic.

So California does not require you to walk into an office, and it does require a real clinical evaluation, which a telehealth clinic should be able to describe step by step.

Our Prescribing

Does Protocol Health Prescribe Semaglutide and Tirzepatide in California?

Protocol Health prescribes compounded semaglutide and compounded tirzepatide to patients in California when a licensed provider decides treatment is appropriate. We are licensed in New York, New Jersey, Connecticut, Florida and California, and the provider who treats you is authorized to practice in the state where you are located.

Prescribing is not automatic. Your provider reviews your history, your goals and your labs, and may recommend semaglutide, tirzepatide, a different approach or no medication at all. Our semaglutide and tirzepatide pages describe each medication, and neither page promises a result.

Both are incretin-based medicines for chronic weight management (tirzepatide acts on GIP as well as GLP-1), and both carry a boxed warning. In rodents they caused thyroid C-cell tumors, and it is unknown whether they do in humans. Each is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, according to the Wegovy labeling and the Zepbound labeling.

Whichever drug a patient asks about, the same screening applies.

So Protocol Health does prescribe both medications in California, after a screening that can end in a decision not to prescribe.

Brand vs Compounded

What Is the Difference Between Compounded and Brand-Name Semaglutide?

The difference between compounded and brand-name semaglutide is that the brand products are FDA-approved finished drugs and compounded versions are not. Wegovy and Zepbound went through FDA review of their safety, effectiveness and manufacturing quality, and they come in fixed, pre-measured pens. A compounded product is prepared by a pharmacy for an individual patient on a prescription and does not go through that review.

The FDA says unapproved versions do not undergo FDA's review for safety, effectiveness and quality before they are marketed, and that compounded drugs should be used only when a patient's medical needs cannot be met by an approved drug. The brand-name trial results quoted on this page belong to the brand products. They are not proof of what a compounded product does, and we never say otherwise.

Compounded semaglutide and tirzepatide spread while both drugs were on the FDA shortage list. As of the FDA's April 2026 update, tirzepatide and semaglutide do not appear on its drug shortage list. The agency also reminds compounders that, under section 503A, a pharmacy may compound for an individual patient on a prescription but may not regularly compound products that are essentially copies of a commercially available drug.

Weight loss injections available to California patients by telehealth fall into two groups: approved brand products, and compounded semaglutide or tirzepatide that a pharmacy prepares for an individual prescription.

Brand-name products have real advantages: standardized dosing, approved labeling and a manufacturer behind them. Compounded products can be adjusted for an individual patient, and the tradeoff is less standardization and more dependence on the prescriber and the pharmacy. Our guide to compounded vs brand-name GLP-1s goes deeper on that comparison.

So the two categories share an active ingredient in many cases, but they differ in approval, regulation and consistency, and a patient should decide with that on the table.

FDA Status

Is Compounded Semaglutide FDA Approved?

Compounded semaglutide is not FDA approved. The approved semaglutide products are brand-name drugs such as Wegovy and Ozempic, and the approved tirzepatide products are Zepbound and Mounjaro. The FDA states that compounded versions are not reviewed for safety, effectiveness and quality before they are marketed. A compounded product can be lawful when it is made by a state-licensed pharmacy for an individual patient on a prescription and is not essentially a copy of a commercially available drug, and lawful is not the same thing as approved.

The FDA has also warned about dosing and product problems. It received multiple reports of adverse events, some requiring hospitalization that may be related to dosing errors with compounded injectable semaglutide, and it says it is not aware of a lawful basis for compounding semaglutide with the salt forms, semaglutide sodium and semaglutide acetate. A poison-control case series in the Journal of the American Pharmacists Association described administration errors with compounded semaglutide, including confusion between milliliters, units and milligrams.

That is why the dosing instructions that come with a vial matter. Ask your prescriber and the pharmacy to explain, in milligrams and in the markings on your syringe, exactly how to measure each dose, and call before you inject if anything is unclear.

So compounded semaglutide is unapproved by definition, can be lawfully prescribed, and carries a measurement risk that a careful prescriber and pharmacy are meant to remove.

Pharmacy

Where Is Compounded Semaglutide Filled and Shipped in California?

Compounded semaglutide for a California patient is dispensed by a state-licensed pharmacy and shipped to your home. Business and Professions Code 4112 treats any pharmacy outside the state that ships dangerous drugs into California as a nonresident pharmacy, and a person may not act as one without a license from the California Board of Pharmacy.

The FDA's advice points the same way: fill the prescription at a state-licensed pharmacy and ask the compounder or the telehealth platform how to measure and give the dose. Before you start, ask which pharmacy fills your order, how it is licensed, and how to reach a pharmacist with a dosing question.

Medication is shipped to your home address and a blood draw, if ordered, happens at a lab near you. Neither step requires a Protocol Health office in California, and we do not have one.

So the pharmacy is part of the safety picture, and a California patient should be able to name it and confirm its license.

Comparison

Semaglutide vs Tirzepatide: Which Works Better for Weight Loss in California?

Semaglutide and tirzepatide are both effective for weight loss, and in a head-to-head trial tirzepatide produced more. In SURMOUNT-5, a 72-week open-label trial of 751 adults with obesity but without diabetes, average weight change was -20.2% with tirzepatide and -13.7% with semaglutide. The maximum tolerated dose in that trial was 10 mg or 15 mg for tirzepatide and 1.7 mg or 2.4 mg for semaglutide, and Eli Lilly funded it.

The placebo-controlled trials tell the same story separately, with the same caution that different trials enrolled different people. The table lists the headline results of each drug's pivotal trial.

TrialDrug and weekly dose usedDurationAverage weight changePlacebo
STEP 1 (1,961 adults)Semaglutide 2.4 mg68 weeks-14.9%-2.4%
SURMOUNT-1 (2,539 adults)Tirzepatide 5 mg72 weeks-15.0%-3.1%
SURMOUNT-1Tirzepatide 10 mg72 weeks-19.5%-3.1%
SURMOUNT-1Tirzepatide 15 mg72 weeks-20.9%-3.1%

These figures come from STEP 1 and SURMOUNT-1, both in adults with obesity or overweight and without diabetes, and they report what happened regardless of whether people stayed on treatment. The doses listed are the doses the trials used, not instructions for any individual. Novo Nordisk funded STEP 1 and SELECT; Eli Lilly funded SURMOUNT-1.

Averages hide a wide spread, and gastrointestinal effects were the most common adverse events with both drugs. Which medicine suits you depends on your history, tolerability, cost and goals, and a clinician makes that call. Our guide to tirzepatide for weight loss covers the tirzepatide evidence in more detail.

So tirzepatide produced larger average weight loss in the one head-to-head trial, and neither drug is automatically right for a given person.

Side Effects

What Are the Side Effects of Semaglutide and Tirzepatide in California?

The side effects of semaglutide and tirzepatide are mostly gastrointestinal, and they are the same in California as anywhere. In the Wegovy labeling nausea was reported by 44% of adults on semaglutide 2.4 mg versus 16% on placebo, diarrhea by 30% versus 16%, vomiting by 24% versus 6% and constipation by 24% versus 11%. In the pooled weight-reduction trials in the Zepbound labeling nausea ranged from 25% to 29% across tirzepatide doses versus 8% on placebo, and diarrhea from 19% to 23% versus 8%.

Most of these effects were mild to moderate and clustered around dose increases. More people did stop treatment because of them: in STEP 1, discontinuation for gastrointestinal events was 4.5% on semaglutide versus 0.8% on placebo, and in SURMOUNT-1 adverse events ended treatment in 4.3%, 7.1% and 6.2% on tirzepatide 5, 10 and 15 mg versus 2.6% on placebo.

Serious risks are less common but real. The labels list pancreatitis, gallbladder disease, dehydration that can injure the kidneys and serious allergic reactions, along with the boxed warning about thyroid C-cell tumors. In SELECT, 17,604 adults aged 45 or older with established cardiovascular disease and overweight or obesity but no diabetes took semaglutide 2.4 mg or placebo, and the semaglutide group had fewer major cardiovascular events (cardiovascular death, nonfatal heart attack or stroke), 6.5% versus 8.0%, while adverse events led to permanent discontinuation in 16.6% versus 8.2%. That is a benefit and a cost in the same study.

Compounded products have not been measured against those trial rates, and the added risks sit in dosing and quality. Call your prescriber for severe or persistent abdominal pain, vomiting that stops you keeping fluids down, a neck lump or signs of an allergic reaction.

So the common side effects are digestive and usually ease, the serious ones are rare, and stopping or adjusting the plan is a decision for you and your prescriber.

Who Should Not

Who Should Not Take Semaglutide or Tirzepatide in California?

People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not take semaglutide or tirzepatide in California or anywhere else. Both labels list that history as a contraindication under the boxed warning (Wegovy, Zepbound), and so does a prior serious allergic reaction to the medicine.

Other groups need a careful conversation first: people with a history of pancreatitis, gallbladder disease, severe gastroparesis or diabetic eye disease, people taking insulin or sulfonylurea drugs because of low blood sugar risk, and anyone who is pregnant, planning pregnancy or breastfeeding. The Wegovy label advises stopping at least 2 months before a planned pregnancy.

Tell every clinician and anesthesia team that you take a GLP-1 medicine before any procedure, because the labels report aspiration risk under anesthesia. Medication is also not the whole treatment. Nutrition, protein intake, strength training and sleep shape what you keep.

Stopping has consequences too. In the STEP 1 extension of 327 participants, who were followed off treatment as an exploratory analysis, people regained 11.6 of the 17.3 percentage points they had lost within a year of stopping, which the authors read as a sign that obesity is chronic and may need ongoing treatment.

So the people who should not take these drugs are defined by thyroid cancer history, allergy and pregnancy plans, and your screening is where that gets found.

At Protocol Health

Weight Loss Clinic in California at Protocol Health

Weight loss clinic care in California at Protocol Health runs by video and mail, with a licensed provider, a real medical history and no promised result. We are a physician-led longevity practice in Scarsdale, New York, licensed in New York, New Jersey, Connecticut, Florida and California, and Scarsdale is the only place we see anyone in person.

Here is how it works for a California patient. You complete a short health assessment, a licensed provider reviews your history and any labs, and the provider decides whether medication is appropriate and which one. If so, a state-licensed pharmacy dispenses it and ships it to you, and follow-up visits by video track side effects and progress. We prescribe compounded semaglutide and compounded tirzepatide, which is a commercial interest, and compounded products are not FDA-approved and are not the same as the brand products tested in the trials above.

Read about our medical weight loss program or take the Protocol Health quiz to start. If medication does not suit you, your provider will say so.

So a weight loss clinic in California at Protocol Health means licensed telehealth care with a screening step that can say no, and Scarsdale stays our only in-person room.

FAQ

Frequently Asked Questions

Is telehealth weight loss legal in California?

Yes, when the prescriber holds a California medical license. The Medical Board of California says telehealth is allowed when it is practiced by a California licensed physician, and the standard of care is the same as in person.

Do you need an in-person visit for semaglutide in California?

No. California Business and Professions Code 2242 says an appropriate prior examination can be achieved through telehealth, including a questionnaire, if the standard of care is met. A clinician still has to evaluate you first.

Is compounded semaglutide FDA approved?

No. FDA approval applies to the brand-name products, not to compounded versions. Compounded versions are not reviewed by the FDA for safety, effectiveness and quality, though a state-licensed pharmacy can lawfully compound them for an individual patient on a prescription.

Does Protocol Health have an office in California?

No. Our only in-person clinic is in Scarsdale, New York. We treat California patients by telehealth and are licensed in New York, New Jersey, Connecticut, Florida and California.

Is tirzepatide better than semaglutide for weight loss?

In the one head-to-head trial, SURMOUNT-5, average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide over 72 weeks. Tolerability, history and goals still decide which medicine fits a person.

Who should not take semaglutide or tirzepatide?

Anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and anyone allergic to the drug. Pregnancy plans, pancreatitis and gallbladder disease call for a careful discussion first.

What are the side effects of GLP-1 weight loss medication?

Nausea, diarrhea, vomiting and constipation are the most common, mostly mild to moderate and tied to dose increases. Serious risks include pancreatitis, gallbladder disease and dehydration, plus a boxed warning about thyroid C-cell tumors seen in rodents.

Explore

Related at Protocol Health

Talk to a provider about weight loss

Medical disclaimer

This article is for education only and is not medical advice, diagnosis, or treatment. Talk to a licensed clinician before starting, stopping, or changing any medication.

Important safety information

Compounded medications are not FDA-approved and are not the same as brand-name products.

References

  1. the standard of care is the same whether the patient is seen in person or through telehealth. mbc.ca.gov. https://www.mbc.ca.gov/Resources/Medical-Resources/telehealth.aspx
  2. Business and Professions Code 2290.5. leginfo.legislature.ca.gov. https://leginfo.legislature.ca.gov/faces/codes_displaySection.xhtml?lawCode=BPC&sectionNum=2290.5
  3. Business and Professions Code 2052. leginfo.legislature.ca.gov. https://leginfo.legislature.ca.gov/faces/codes_displaySection.xhtml?lawCode=BPC&sectionNum=2052
  4. Business and Professions Code 2242. leginfo.legislature.ca.gov. https://leginfo.legislature.ca.gov/faces/codes_displaySection.xhtml?lawCode=BPC&sectionNum=2242
  5. Wegovy labeling. National Institutes of Health. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  6. Zepbound labeling. National Institutes of Health. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  7. do not undergo FDA's review for safety, effectiveness and quality before they are marketed. U.S. Food and Drug Administration. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  8. tirzepatide and semaglutide do not appear on its drug shortage list. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  9. case series in the Journal of the American Pharmacists Association. PubMed. https://pubmed.ncbi.nlm.nih.gov/37392810/
  10. Business and Professions Code 4112. leginfo.legislature.ca.gov. https://leginfo.legislature.ca.gov/faces/codes_displaySection.xhtml?lawCode=BPC&sectionNum=4112
Show all 15 references
  1. -20.2% with tirzepatide and -13.7% with semaglutide. PubMed. https://pubmed.ncbi.nlm.nih.gov/40353578/
  2. STEP 1. PubMed. https://pubmed.ncbi.nlm.nih.gov/33567185/
  3. SURMOUNT-1. PubMed. https://pubmed.ncbi.nlm.nih.gov/35658024/
  4. adverse events led to permanent discontinuation in 16.6% versus 8.2%. PubMed. https://pubmed.ncbi.nlm.nih.gov/37952131/
  5. 11.6 of the 17.3 percentage points they had lost within a year of stopping. PubMed. https://pubmed.ncbi.nlm.nih.gov/35441470/

Why trust our physicians

Every article is reviewed by a licensed physician on our medical team and is kept current by our editorial team. Read our editorial policy and our medical review process.

Medically reviewed by
Richard Dentico, MD on
Written by
Protocol Health Editorial Team
First published
Last updated

See an error? Email care@protocolhealthmd.com and we will review it.

More on GLP-1 & Weight Loss

All Weight Loss articles →